Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **tetanus neurotoxin heavy chain C-terminal domain** (Hc-TeTx) is a ~50 kDa domain of the larger tetanus neurotoxin (TeNT) produced by *Clostridium tetani*. TeNT consists of a light chain with zinc-protease activity and a heavy chain comprising two domains: the N-terminal (translocation) and the C-terminal (binding) domains[1][6]. The C-terminal domain is responsible for the highly selective binding of the neurotoxin to neural cell surface receptors—primarily polysialogangliosides (such as GD2, GD1b, and GT1b)—and a specific, possibly GPI-anchored protein, allowing entry into neurons and retrograde transport to the spinal cord[2][1][3][6]. While the full toxin is the causative agent of spastic paralysis (tetanus), the **Hc-TeTx domain itself** is being investigated as a vehicle for neuronal delivery and for its potential neuroprotective effects in neurodegenerative disease models such as amyotrophic lateral sclerosis, independent of the neurotoxin’s paralytic enzyme activity[3]. The domain’s high affinity and specificity for neurons make it an attractive scaffold for engineering targeted therapies or imaging agents, though its clinical application is limited primarily by concerns of immunogenicity and molecular safety (in the absence of catalytic LC activity)[3][1].
Mediates binding of tetanus neurotoxin to motor neuron terminals and internalization via ganglioside (and putative protein) receptor interaction[2][1]; Enables neurotrophin-like, PI3K/Akt pathway modulation for neuroprotection in preclinical models[3]
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tetanus neurotoxin heavy chain C-terminal domain (Hc-TeTx).